Trial Profile
A Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety and Efficacy of Allogeneic Human Mesenchymal Stem Cells in Patients With Metabolic Syndrome
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 17 Feb 2023
Price :
$35
*
At a glance
- Drugs Mesenchymal stem cell therapy-Longeveron (Primary)
- Indications Metabolic disorders
- Focus Therapeutic Use
- Acronyms SIRONA
- Sponsors Longeveron
- 14 Feb 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 14 Feb 2023 Planned initiation date changed from 1 Dec 2022 to 1 Dec 2023.
- 04 Mar 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.